Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.51 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | COMT | P21964 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17849877 | 0.72 | CRBN (0.44) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| SCHEMBL12111086 | 0.71 | TOP2A (0.51) | TOP2ATOP2BPTGS1LMNAPIK3CD | |
| SCHEMBL12108576 | 0.70 | PTGS1 (0.46) | TOP2ATOP2BPTGS1LMNAPIK3CD | |
| SCHEMBL27775549 | 0.69 | PIK3CD (0.48) | TOP2ATOP2BPTGS1LMNAPIK3CD | |
| Dexrazoxane SCHEMBL18400 | 0.68 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAPIK3CD | |
| Razoxane SCHEMBL3339694 | 0.68 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAPIK3CD | |
| Dexrazoxane SCHEMBL1586271 | 0.68 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAPIK3CD | |
| Razoxane SCHEMBL9089 | 0.68 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAPIK3CD | |
| SCHEMBL839300 | 0.67 | TOP2A (0.46) | TOP2ATOP2BPTGS1LMNAPIK3CD | |
| SCHEMBL9967746 | 0.67 | PIK3CD (0.55) | TOP2ATOP2BPTGS1LMNAPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107179-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2017-04-20 | — | — | US | disclosed |
| US-9371283-B2 | Polycyclic tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107179-A1 | Polycyclic Tetracycline Compounds | TET1, TUBA1C, TUBB | TOP2A 122/4885TOP2B 99/4885PTGS1 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.